Report of Foreign Issuer (6-k)
April 17 2018 - 8:48AM
Edgar (US Regulatory)
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For
period ending
17 April
2018
GlaxoSmithKline plc
(Name
of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or
will
file annual reports under cover Form 20-F or Form 40-F
Form
20-F x Form 40-F
--
Indicate
by check mark whether the registrant by furnishing the
information
contained in this Form is also thereby furnishing the
information
to the Commission pursuant to Rule 12g3-2(b) under the
Securities
Exchange Act of 1934.
Yes
No x
GlaxoSmithKline plc (the
'
Company
')
GlaxoSmithKline plc (the
'
Company
')
Transaction notification
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Ms E Walmsley
|
|
b)
|
Position/status
|
Chief
Executive Officer
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of
the financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature of
the
transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 12 April 2018.
|
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
|
£14.3999
|
1885.380
|
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2018-04-12
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr R G Connor
|
|
b)
|
Position/status
|
President, Global Manufacturing & Supply
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of
the financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of
the
transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 12 April 2018.
|
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
|
£14.3999
|
820.907
|
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2018-04-12
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr L Debruyne
|
|
b)
|
Position/status
|
President, Global Vaccines
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of
the financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature of
the
transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 12 April 2018.
|
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
|
£14.3999
|
1360.326
|
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2018-04-12
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr S Dingemans
|
|
b)
|
Position/status
|
Chief Financial Officer
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of
the financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of
the
transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 12 April 2018.
|
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
|
£14.3999
|
1289.846
|
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2018-04-12
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr D S Redfern
|
|
b)
|
Position/status
|
Chief Strategy Officer
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of
the financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature of
the
transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 12 April 2018.
|
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
|
£14.3999
|
2388.623
|
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2018-04-12
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Ms C Thomas
|
|
b)
|
Position/status
|
SVP, HR
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of
the financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature of
the
transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 12 April 2018.
|
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
|
£14.3999
|
1514.507
|
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2018-04-12
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr P C Thomson
|
|
b)
|
Position/status
|
President,
Global Affairs
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of
the financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature of
the
transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 12 April 2018.
|
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
|
£14.3999
|
1262.984
|
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2018-04-12
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mrs K Thomson
|
|
b)
|
Position/status
|
PCA of Mr P C Thomson (President, Global Affairs)
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of
the financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature of
the
transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 12 April 2018.
|
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
|
£14.3999
|
156.475
|
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2018-04-12
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr N Hirons
|
|
b)
|
Position/status
|
SVP, Global Ethics and Compliance
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of
the financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature of
the
transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 12 April 2018.
|
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume(s)
|
|
£14.3999
|
380.094
|
|
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2018-04-12
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: April
17, 2018
|
|
|
|
|
|
|
By: VICTORIA
WHYTE-
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|
GSK (NYSE:GSK)
Historical Stock Chart
From Oct 2024 to Nov 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Nov 2023 to Nov 2024
